PharmaceuticalOralGLP-1 receptor agonistSmall-molecule

Orforglipron

Also known as LY3502970 · OWL833

Written by enwyReviewed 15 Jul 20261 sources0 comments

Orforglipron is an oral, non-peptide small-molecule GLP-1 receptor agonist developed by Eli Lilly, notable for being taken as a daily pill without food or water restrictions. Phase II and Phase III trials show clinically meaningful weight loss and glucose lowering comparable to injectable GLP-1 agonists.

01 Overview

Orforglipron is a small-molecule GLP-1 receptor agonist, distinct from peptide drugs like semaglutide in that it is orally bioavailable as a conventional tablet without the strict fasting requirements of oral semaglutide. This makes it a potentially convenient alternative to injections.

In Phase II obesity and diabetes trials, and reported Phase III results, orforglipron produced substantial weight loss and HbA1c reduction, with a gastrointestinal side-effect profile typical of the class. It is a late-stage investigational drug with a growing body of human data, not yet broadly approved as of this review.

02 Mechanism

Non-peptide small molecule that agonises the GLP-1 receptor, enhancing glucose-dependent insulin secretion, suppressing glucagon, slowing gastric emptying, and increasing satiety.

03 Dosing

Tier	Dose	Route	Notes
Trial range	3–45 mg/day	Oral	Titrated daily doses studied in trials; no food/water restriction.

04 Effects

Effect	Magnitude	Evidence
Weight lossSubstantial weight reduction over months in obesity trials, comparable to injectable GLP-1 agonists.	~8-15% body weight	Clinical
Lowered blood glucose (HbA1c)Significant HbA1c reduction in type 2 diabetes trials.	~1.3-2.1% HbA1c	Clinical

05 Side effects

Effect	Severity	Frequency	Evidence
Reduced appetite / early satietyMarked appetite suppression, intended but occasionally excessive.	Mild	Very common	Clinical
Nausea and GI upsetNausea, vomiting, and diarrhoea, mostly during dose escalation.	Moderate	Very common	Clinical
Pancreatitis (class signal)Rare pancreatitis is a class-level concern for GLP-1 agonists.	Severe	Rare	Clinical

06 Legal status

United States

Investigational / late-stage

Late-stage investigational drug; broad approval pending as of review. · as of Jan 2026

07 References

Orforglipron, an oral small-molecule GLP-1 receptor agonist, in obesity and type 2 diabetesNew England Journal of Medicine, 2023

08 Discussion0 comments

Create account

Discussion is moderated. No sourcing, vendor names or price talk — those comments are removed, and repeat posts are banned.

This page is reference information, not medical advice. Doses and protocols are documented as they appear in the clinical literature and in practice — describing them is not a recommendation to use them. Countermeasures listed here are not a substitute for a physician. Legal status varies by jurisdiction and changes.